Skip to main content

Table 1 Demographic and clinical characteristics of the CHB patients

From: Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls

   HBeAg hepatic steatosis
Total (n = 1185) Positive (n = 658) Negative (n = 527) n = 273 P
Age
Median years 33 (15–67) 31 (15–60) 37 (17–67) 36 (16–67)  
Means ± SD 33 ± 9 31 ± 8A 37 ± 9A 36 ± 9 < .001A
Sex
Female 291 (25%) 180 (27%)B 111 (21%) B 43 (16%)C .012B
Male 894 (75%) 478 (73%)B 416 (79%)B 230 (84%)C < .001C
ALT (U/L)
Means ± SD 153 ± 218 169 ± 216D 133 ± 220D   .005D
TBIL (μmol/L)
< 17 μmol/L (n) 1010 (85%)     
17–50 μmol/L (n) 166 (14%)     
51–100 μmol/L (n) 6 (0.5%)     
101–150 μmol/L (n) 3 (0.25%)     
HBV DNA (log10 IU/L)
Means ± SD 5.97 ± 1.96 6.77 ± 1.14E 4.97 ± 1.43E   < .001E
Hepatic steatosis 273 (23%) 131 (20%)F 142 (27%)F   .004E
  1. Continuous variables are presented as the mean (SD) if normally distributed and median if not. Significant differences among them are reported as P values. A,B C,D,ESignificant differences (P ≤ .05) between groups are indicated as follows:
  2. AFor comparison between HBeAg-positive and HBeAg-negative patients
  3. BFor comparison of females and males who were HBeAg positive and HBeAg negative
  4. CFor comparison of CHB with hepatic steatosis between females and males
  5. DFor comparison of ALT between HBeAg-positive and HBeAg-negative patients
  6. FFor comparison of CHB with hepatic steatosis between HBeAg-positive and HBeAg-negative patients